Loading ...
Global Do...
News & Politics
3
0
Try Now
Log In
Pricing
Bratisl Lek Listy 2010; 111 (3) Indexed and abstracted in Science Citation Index Expanded and in Journal Citation Reports/Science Edition ! "#$ %$&'( #)$**$+ #$"%$)%$,%' #-"$ . $ $# )$**$+#$ "%$,'%/$,0123342)%$,%'- 5'5 *"06 //768447$ *36497:642#;,%' 1 &.-844:69<1"014:- Abstract: Diabetes mellitus is one of the most severe and costly chronic disease of our time. Approximately 2–3 % of diabetics have an active foot ulcer, and 15 % of all patients with diabetes will develop an ulcer during their lifetime. Treatment of foot complications is one of the main items in the absorption of enormous economic and health resources addressed to the diabetic patients. Advances in basic science, tissue culture techniques and cell therapy promise to improve the treatment of diabetes as well as its complications, i.e. also the ischemic ulcers of the foot. At present, the isolation of any specific type of cells, their in vitro expansion and biological characterization of acquired cell population are possible. For the healing process in ischemic diabetic ulcers, stem cells, endothelial progenitor cells and fibroblasts, both in suspension or placed on an extracellular scaf- fold are used. This process is focused on stimulating the new blood vessels formation. This is stimulated by the paracrine secretion of multiple growth factors and their receptors. Verified are the vascular endothelial growth factor and its receptor, fibroblast growth factor, interleukin-8 and proangiogenic cytokines (Ref. 62). Full Text (Free, PDF) www.bmj.sk. Key words: diabetic foot ulcer, cell therapy, tissue engineering, clinical trials. & 831 -$ 1 &3:38444=%8-2>? 9<<8494=%/-/>?=3?- $ - 5 % 53>/-3>$ 4-83@3-9:>=8?- 1 1 5 ' AB1 97<7>=9$/?- A5 'C=D2 5'?$$=B?-% 5 %1 =<$:?$5 1 =2$7?- $ &%% %E=34?- ' 1 $ $ $ '=33?- & %%3B> 844 5 55-1 $ $ =<?-1 FB4>5% &3-#A& -1 3$8B>$893-<>9 <4>-5% $B@34>5 511' 3B@84>5 %11'=33?-# <4>1 55 -#& EC -% &=38?- , $ 1$ $ $ %G- 1 5 -# A 5 %HI$ G 5$%1&$ =39?- %%$ Ulicna M et al. Does cell therapy and tissue engineering represent… %$1 %F& F 5- 5 % 1 5I% = ?5 '% %&'=3/?- $$=1 $% $1 ? I =5 $ $I%? 5-5'5%1 =?$51 $A& - 84> 5I%5 $B4>5% $94>5% =3B?- $ 1 5- ! $%1 5 5 % -.=?%1 5$ % =3<?- 51I1 % A1'=3:$32?- 1 - +$ $ =II ?- " + C % '-+ 5% 5&- 5 $I1 =37?- G '$'-;5%$1 ' 5-+ %% *+1β3 A%*+1β31 -$ *+$+*+18$ *+*+1β % 555=84$83?- % 5A% $ ' =88?- ;5%$ 5 % I ' 5 #5$ '1 =89?- %5%1 $-'1 $ $α 8 $ 5$'% 5=8/?-%5 5 1 %$$$1 %5=8B?- $5% 5 % $1 G $ 6'1 - #!$% =%,6,J.5? A1 -;5 1 $ 1 $'61 55- $ 1I1 I -;$1 5 -& :4>34>55$ 1 - %&I I $1 -+55 1 5 5% %5 ' 1 $1 =8<$8:?- & ! '$ ($)* *'=F$$#$.%1 $ ;%$.(? 11 'C% % "-,- %=82$87?- A %1 C$%1 '-%% ' I5A % AI- ''I 35'- ' '-HI1 I$ % $ '-II1 A %G 1 1=94?-"''$*' Bratisl Lek Listy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licna M et al. Does cell therapy and tissue engineering represent… 5 - 1 &%I=% ? &%I' I=)?$I= 8 ?$ $$%15 5%- 5 %5 =<4?- $MG'9:5 % =--%G% ?5 5=)#,?-5 %%1 $5- I$%1 5- $'1 $)$ $ 8 55 8 %-1 &A%%% )#,=<3?- )#, =?A 51 =#,?%E 1 55C1 5= ?=<8?-E 5 55& 5%51 -I 5#, 5:3:-87 $55%5G$ %' 5 - + 5$1 % %- C$1 % %G1 5 - %%5% 5-% ' 5 ' % - - ./)0- &0&0) -01$* % H8444&8494- 844/F8:H34/:N34B9- 2,+304#5- - 844/F/H/39N/32- 6-&*0, *50)#&5I - -*%1 377B 74#04 -0) #- 51 HA%- 3772 F 83H:92- 8/ ,5- (.377<F89H829N874- 93+ NA%%5-,1 844:FB=/?H837N893- :;404 )3-' - 3773F7HBBBNB<9- <) ,*03;0,- % -#,8449F84H <27N:42- =/)+0#>-0/5)0#&-+ H % -; '# 844:F9H<BN:<- .?#50--,# = ?-,*-(,8444F93H3N87<- ..) -40@54- H% !#3777F394H//8N///- .2# 30 "* H %%5- %844<F=/?H /93N//:- .64;0AB)101A51 HA- ,844<F33:=,?H9BN/3- .73C50> ( A+;I$ # G$ ;-I I , 8442F34=33?H32<7N3228- .8-&*0> 30, *5040)#&0 330,5551I1 5 5- 3777F 88H3B:N3<8- .9$3*0*4+H *+ %$ $ - ) 8449F<7H9<9N9:/- .:#D>0,A0,$ 1 %- 8449F93/H34:N33:- .<)-- 844/F 33:H9N98- .=& 50+ -"- , % O K3 % I $% -(% 1 377<F34<H348N342- 2?$04$$" %% *+1K3- ( ,377:F3<HB7N<<- 2.+ #40E*C0$ 1 '5-,37//F837H<22N<78- 22# /+0" 50-)1% 5-( # 844/F27H2/:N2B3- Bratisl Lek Listy 2010; 111 (3) 26/)50) 4503 %I1 1819 -)( 8449F3/7H39N3<- 27">0*/$-%1 -3779F93/H344<N3442- 28)5;0">-%%5-(1 #,8449F:H3837N88/- 29450310-*0 -0- 0% &1*5 H1 - # 3777FBH8<BN:7- 2:4;0$505/&0$1 1 %I%- 8449F33=/?H878N87<- 2<,*0* $0,#50 D;% %'1C%'-,1 3723F833H34B8N34B/- 2=*/$0@403 1HA' =*'?5HI- , 377BF83H297N2/9- 6?#;30>- - ,844<F33:=:?H3B8N3B:- 6.,$0E50; %+ 40@ +0* $1 %'C% =;, ? -,8449F33H 89N93- 62>0">0#&0) 43-*'$ ; ,' C%$ % # .1 . + "- 8443F 8/H 874N87B- 66*4 +"1 ,*- -(5 I8447F2=3?H33N32- 67;50@ %*50) ))0/ 40)% 5504>)0554 % -,3772F828H33/BN33/:- 681/0,04/0+5/0 $- ) 844BF:8H3484N3482- 69, #0)30;-)H1 G$$-( ##844/F2H943N93<- 6:+"$0;-)#- 8442F34H889- 6<E E0E)0) E01;0$D10 A 10$>50E 10$) 1 5I 5%1 I 5- )( 844/F3B3=B?H3437N3482- 6=%10* 04#03D303 % 10& 5 5 *+1%%-*8449F34H <83N<87- 7?&-01,0$ 0>F%1 403 G0" 4,0/ &)5% %% 1 - 844BF33H27<N749- 7.1;0)*0,4)03+/0,)0" )0 * )*#51% I ' % %%- 844/F 7/H<:2N<2B- 72;04$0; ;01 +0+0) 40140440@54)51 %1 %G- 3777F 2BH 883N882- 76"@0-/-%1 %- %3778F33<H/9BN/97- 77$/ 5 - 0, *#3744F88H3:3N982- 78/450A )$% -.5 - ( %377<F7:H B73NB7B- 7910; % "-G1 %%844:F:4H/::N/2/- 7:&+0#D*;H '- )377:F3:H3379N3848- 7<$40*/0/+ H 1 G$ $ - ) 8449F89H332BN3327- 7=,)40,-50> ( A+$1 $5- %, 844BF97=/?H879N94B- 8?; A40&-#0+ 5401 +0&505 % &-0350&&+; I $ $ % - 8448F 34<H 8:23N8:2<- 8.1 +04$0; ;01 %4/40)40 1403;0@540;I%% I %G1 -.,",8444F7:H9/88N9/8:- 82A #01D50+)0,#4030 5 -.P,8443F792H883N887- 861)0&*0&150) A40;0 )"/0- *0440) "500) )0, 5045*5+1%1 II%%-.#8443F :H 349BN34/4- 87)40)010;D0A )0; ;0 $$04 40$E0--; % -.#8448F2H/49N/47- 88&4,04/)0+)0,&0& )40 4-0,,50>;0) *0 ,0) */ % 1 %%G-.#8448F2H<4:N<38- Ulicna M et al. Does cell therapy and tissue engineering represent… 89E0$0)4) *+ 51%= ?%1 5 -.,",8448F 77H 337B3N337B<- 8:3#0$10#)0++0, 0,30+% 0$,04 /0/30/E0$ #0CC0 $ -0+-&0440$DD10410,% -0-) 151%1 ' 5-.#8443F:H337/N3843- 8<E$04)0CD*#0%&0A 403&0A 501 50, #/399$ .% #' ;; , -) 377:F74=38?HB448NB438- 8=, 3)0# +01H 0&&0@ &01% -0)40440+ @04 40)0+% 04&0)30&0*+0 4; 399L; " , %,- 8447F3B8/N/B:3- 9?&E0C50I3%1 5 5 5 -QR+ ( 0QQ844:F83=:?H<:BN<:2- 9. J >0& 50+J50101&30 5 ;0+ K#01D 5 5 51 1 -'8447FBB=9?H3:9N3:2- 92>DLLJ 50#LM301L40, L#05J 30GMJ 40,L 4 1 -. 844<F8:=,8?H 39/N39:- %#94$8447- (B$8434-